Actively Recruiting
CTNNA1 Familial Expansion Study
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-02-05
100
Participants Needed
1
Research Sites
354 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.
CONDITIONS
Official Title
CTNNA1 Familial Expansion Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age and older
- Carrier or first-degree relative of a carrier of a CTNNA1 loss-of-function variant, including nonsense, frameshift, large exon deletions, or splice site variants
- Ability to understand and read English
- Ability to provide informed verbal or written consent
You will not qualify if you...
- Younger than 18 years old
- Do not carry a CTNNA1 loss-of-function variant and are not a first-degree relative of a carrier
- Cannot speak or read English
- Major psychiatric illness or cognitive impairment preventing participation
- Unable to comply with study procedures as judged by study staff
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
B
Bryson W Katona, MD, PhD
CONTACT
D
Dana Farengo Clark, MS, LCGC
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here